Last reviewed · How we verify
Sintilimab Combined With Docetaxel Monotherapy
Sintilimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.
Sintilimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Non-small cell lung cancer, PD-L1 negative.
At a glance
| Generic name | Sintilimab Combined With Docetaxel Monotherapy |
|---|---|
| Also known as | Sintilimab Combined With Paclitaxel Monotherapy, Sintilimab Combined With Irinotecan Monotherapy, Camrelizumab Combined With Docetaxel Monotherapy, Camrelizumab Combined With Paclitaxel Monotherapy, Camrelizumab Combined With Irinotecan Monotherapy |
| Sponsor | Ye jinjun |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By blocking the PD-1 receptor, sintilimab enhances the body's immune response against cancer cells, leading to their destruction. This mechanism is particularly effective in treating various types of cancer. Sintilimab, when combined with docetaxel, has shown promising results in clinical trials.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Non-small cell lung cancer, PD-L1 negative
Common side effects
- Pneumonitis
- Fatigue
- Nausea
Key clinical trials
- Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy (PHASE3)
- Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: